Publications by authors named "Michael B Cooper"
beta-amyloid (Abeta) arises from an amyloid precursor protein (APP) via beta- and gamma-secretase proteolysis. Platelets are the primary depot of APP in the circulation and may be a source of cerebral Abeta. We measured the platelet activities of alpha- and beta-secretases in normal individuals.
View Article and Find Full Text PDFObjective: Reduced insulin sensitivity associated with fasting hyperproinsulinaemia is common in type 2 diabetes. Proinsulinaemia is an established independent cardiovascular risk factor. The objective was to investigate fasting and postprandial release of insulin, proinsulin (PI) and 32-33 split proinsulin (SPI) before and after sensitization to insulin with pioglitazone compared to a group treated with glibenclamide.
View Article and Find Full Text PDFArticle Synopsis
- The RISK pathway, involving PI3K-Akt/PKB and p44/42 MAPK, plays a key role in protecting the heart from ischemia-reperfusion injury, but the timing of its activation during reperfusion is not well understood.
- The study used mouse hearts to analyze the phosphorylation of Akt and p44/42 and their activity after ischemia and different reperfusion periods, with and without apelin-13, a potential cardioprotectant.
- Results showed that while phosphorylation of Akt and p44/42 increased over time during reperfusion, increased kinase activity was only observed with apelin treatment, suggesting that both phosphorylation and activity are important for cardioprotective effects.
Article Synopsis
- The study explores how high levels of LDL (low-density lipoprotein), especially when oxidized, affect blood vessel responses to beta-amyloid (Abeta) in a context relevant to aging and Alzheimer's disease (AD).
- It was found that soluble forms of Abeta (specifically Abeta40 and Abeta42) combined with oxidized LDL led to increased constriction of blood vessels and decreased relaxation responses, showing a potential link between cholesterol levels and vascular issues in AD.
- This indicates that managing hypercholesterolemia could be a crucial factor in addressing cerebrovascular problems associated with Alzheimer's, highlighting new pathways for potential treatments.